Posted by Michael Wonder on 28 Apr 2022
FDA approves Mycovia Pharmaceuticals’ Vivjoa (oteseconazole), the first and only FDA approved medication for recurrent vulvovaginal candidiasis
28 April 2022 - U.S. commercial launch of Vivjoa expected in Q2,
The U.S. FDA approved Vivjoa (oteseconazole capsules), an azole anti-fungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis in females with a history of recurrent vulvovaginal candidiasis who are not of reproductive potential.
